REGENERON PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
REGN$919.96+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
As disclosed in the table below, during the three months ended March 31, 2024, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
| Name | Position | Date of Plan Adoption | Scheduled End Date of Trading Arrangement(a) | Total Number of Securities to Be Sold Under the Plan |
|---|---|---|---|---|
| Bonnie L. Bassler, Ph.D. | Director | 2/27/2024 | 4/30/2025 | 3,851 |
| Michael S. Brown, M.D. | Director | 2/26/2024 | 8/31/2024 | 2,707 |
| Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary | 2/16/2024 | 2/10/2025 | 5,191 |
| Marion McCourt | Executive Vice President, Commercial | 2/13/2024 | 5/31/2025 | 8,122 |
| Leonard S. Schleifer, M.D., Ph.D. | Board co-Chair, President and Chief Executive Officer | 2/5/2024 | 8/5/2025 | 229,204 |
| George D. Yancopoulos, M.D., Ph.D. | Board co-Chair, President and Chief Scientific Officer | 2/14/2024 | 2/10/2025 | 100,000 |
| (a) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.